Zobrazeno 1 - 10
of 78
pro vyhledávání: ''
Publikováno v:
British Journal of Cancer
Background Some endogenous hormones have been associated with breast cancer risk, but the nature of these relationships is not fully understood. Methods UK Biobank was used. Hormone concentrations were measured in serum collected in 2006–2010, and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d482614b3e60f0e3b3fcf0d952cf3d1b
https://ora.ox.ac.uk/objects/uuid:2298adb9-eb05-46ad-ae36-48abd7ac39d1
https://ora.ox.ac.uk/objects/uuid:2298adb9-eb05-46ad-ae36-48abd7ac39d1
Autor:
Mari K. Halle, Marte Sødal, Hilde Engerud, David Forsse, Bjørn I. Bertelsen, Camilla Krakstad, Ingfrid S. Haldorsen, Kari Strøno Wagner-Larsen, Njål G. Lura, Jone Trovik, Kathrine Woie, Akinyemi I. Ojesina
Publikováno v:
British Journal of Cancer
Background Advanced cervical cancer carries a particularly poor prognosis, and few treatment options exist. Identification of effective molecular markers is vital to improve the individualisation of treatment. We investigated transcriptional data fro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::839b54a851051f73e14419c2d53c21d6
https://hdl.handle.net/11250/2830881
https://hdl.handle.net/11250/2830881
Autor:
David Smith, Roberto Pili, Farhad Sedarati, Shadia I. Jalal, Andrés Cervantes, Martin H. Voss, Howard A. Burris, Rachel Neuwirth, Teresa Macarulla, Douglas V. Faller, Michael S. Gordon, Monica M. Mita, Vicky Makker, Igor Puzanov, Ding Wang, A. Enke, Brian I. Rini, Shubham Pant, Manish R. Patel, Yaping Shou
Publikováno v:
Scientia
British Journal of Cancer
British Journal of Cancer
Background This Phase 1 dose-escalation/expansion study assessed safety/tolerability of sapanisertib, an oral, highly selective inhibitor of mTORC1/mTORC2, in advanced solid tumours. Methods Eligible patients received increasing sapanisertib doses on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04304289ca3485f1a4178792263b5785
https://hdl.handle.net/11351/6503
https://hdl.handle.net/11351/6503
Autor:
Rainer Georg Goeldner, Li-Tzong Chen, Alan Anthoney, Karim Rihawi, Ann-Lii Cheng, Maria Jove, Susanne Buschke, Jesus Corral, Vasiliki Michalarea, Jih-Hsiang Lee, Thomas Bogenrieder, Her Shyong Shiah, René Fuertig, Michael Ong, Ulrike Schmid, Chia-Chi Lin, Dennis Chin-Lun Huang, Chih-Hung Hsu, Johann S. de Bono, James Chih-Hsin Yang, Chia Jui Yen, Chris Twelves, Natalja Strelkowa
Publikováno v:
British Journal of Cancer
Background Xentuzumab, an insulin-like growth factor (IGF)-1/IGF-2-neutralising antibody, binds IGF-1 and IGF-2, inhibiting their growth-promoting signalling. Two first-in-human trials assessed the maximum-tolerated/relevant biological dose (MTD/RBD)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a29e29df9b254be8f87f8fcc43c3fad
Autor:
Sylwia Kopijasz, Corran Roberts, Victoria Y Strauss, Shibani Nicum, Andrew R Clamp, Marcia Hall, Richard D. Kennedy, Ana Montes, Charlie Gourley, Jacinta Abraham, Michael R.L. Stratford, Susana Banerjee, Lisa K. Folkes
Publikováno v:
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4, https://doi.org/10.1038/s41416-019-0674-4
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
Roberts, C, Strauss, V Y, Kopijasz, S, Gourley, C, Hall, M, Montes, A, Abraham, J, Clamp, A, Kennedy, R, Banerjee, S, Folkes, L K, Stratford, M & Nicum, S 2020, ' Results of a phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA-defective tumours ', British Journal of Cancer, vol. 122, no. 4, pp. 483-490 . https://doi.org/10.1038/s41416-019-0674-4
British Journal of Cancer
BackgroundTumour cells with BRCA1/2 gene mutations demonstrate increased sensitivity to platinum and poly (ADP-ribose) polymerase (PARP) inhibitors. 6-mercaptopurine (6MP) was found to selectively kill BRCA-defective cells in a xenograft model as eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f2b494bdec4a88dbce8776a6e9b65b9c
https://doi.org/10.1038/s41416-019-0674-4
https://doi.org/10.1038/s41416-019-0674-4
Autor:
Trong Nghia Nguyen-Dobinsky, Andreas Kurtz, Julian Veelken, Ingo Pilgermann, Anke Guhr, Kajetan von Eckardstein, Amanjit Gill, Quang Long Nguyen, Anja Elstner, Tingguo Zhang, Thomas Picht, Robert L. Martuza, Florian Stockhammer, Andreas von Deimling
Publikováno v:
Journal of Neuro-Oncology
Diagnosis of a glioblastoma (GBM) is triggered by the onset of symptoms and is based on cerebral imaging and histological examination. Serum-based biomarkers may support detection of GBM. Here, we explored serum protein concentrations of GBM patients
Publikováno v:
Gupta, Samir; Wang, Furong; Holly, Elizabeth A.; & Bracci, Paige M.(2010). Risk of pancreatic cancer by alcohol dose, duration, and pattern of consumption, including binge drinking: a population-based study. Cancer Causes & Control: An International Journal of Studies of Cancer in Human Populations, 21(7), pp 1047-1059. doi: 10.1007/s10552-010-9533-6. Retrieved from: http://www.escholarship.org/uc/item/696721j2
Cancer Causes & Control
Cancer Causes & Control
Alcohol consumption is postulated to be a risk factor for pancreatic cancer (PCA), but clarification of degree of risk related to consumption characteristics is lacking. We examined the association between alcohol consumption and PCA in a population-
Autor:
Biljana Mihaljevic, Radmila Živkovic, Branka Filipovic, Jelena Hajder, Tamara Martinovic, Natasa Stanisavljevic, V. Cemerikic-Martinovic, Dejana Stanisavljevic, Olivera Markovic, Dragomir Marisavljevic
Publikováno v:
Medical Oncology (Northwood, London, England)
Survivin is one of the inhibitors of apoptosis proteins (IAP) that might play an important role in the pathogenesis of diffuse large B cell lymphoma (DLBCL). The present study was designed to investigate the clinical and prognostic significance of su
Autor:
Jonathan L. Wright, Janet L. Stanford
Publikováno v:
Cancer Causes & Control
Purpose Metformin is a commonly used medication for type II diabetes mellitus. Epidemiologic studies have suggested a decreased relative risk of cancer with metformin use, and preclinical studies of prostate cancer (PCa) have shown antitumor activity
Autor:
Magda A Blaut, Thilo Dörk, Michael Bremer, Natalia Bogdanova, Evgeny N. Imyanitov, Hans Christiansen, Aglaya G. Iyevleva, Svetlana N. Abysheva, Anna P. Sokolenko, Margret Rave-Fränk
Publikováno v:
Breast Cancer Research and Treatment
Since germline mutations in the PALB2 (Partner and Localizer of BRCA2) gene have been identified as breast cancer (BC) susceptibility alleles, the geographical spread and risks associated with PALB2 mutations are subject of intense investigation. Pat